肝细胞癌中的免疫表型和瘤免疫微环境 具有巨大的巨细胞和容器封装瘤群的肝细胞癌
Jun Akiba1, Masamichi Nakayama2, Reiichiro Kondo2
1Department of Diagnostic Pathology, Kurume University Hospital, Kurume, Japan; akiba@med.kurume-u.ac.jp.
In vivo (Athens, Greece)
|February 28, 2024
概括
与封装瘤集群的血管 (VETC) 相比,巨型瘤巨型 (MTM) -肝细胞癌 (HCC) 呈现出不同的免疫表型和瘤免疫微环境 (TIME). 这两种模式都显示免疫抑制的时间,需要策略来增强免疫检查点抑制剂的有效性.
科学领域:
- 肝细胞癌研究 肝细胞癌研究
- 瘤免疫学 瘤免疫学
- 癌症生物标志物 癌症生物标志物
背景情况:
- 肝细胞癌 (HCC) 呈现出激进的组织学模式,包括巨细胞巨型 (MTM) 和瘤集群封装血管 (VETC).
- 这些模式与免疫抑制性瘤免疫微环境 (TIME) 相关.
- 有限的研究存在于MTM-HCC和VETC-HCC免疫类型和TIME的同时比较.
研究的目的:
- 调查和比较MTM-HCC和VETC-HCC的免疫类型和时间.
- 为了确定这些HCC亚型之间的免疫细胞透和标记物表达的差异.
- 了解免疫检查点抑制剂治疗对免疫检查点抑制剂治疗的影响.
主要方法:
- 74例HCC病例的免疫组织化学分析 (32例MTM-HCC,21例VETC-HCC,21例常规HCC).
- 对肝细胞标记物 (HepPar-1),茎状标记物 (Keratin19,CA IX),PD-L1表达和CD8透的评估.
- 统计分析以比较分组之间的标记体表达和免疫细胞透.
主要成果:
- 与其他HCC类型相比,MTM-HCC的HepPar-1表达频率较低.
- 在MTM-HCC中,Keratine19,碳酸酶 (CA) IX和PD-L1表达的频率较高.
- 在MTM-HCC (34.4%) 中,PD-L1表达显著高于VETC-HCC (0%) 和常规HCC (19.0%).
- PD-L1表达与瘤茎和缺氧标志物相关联.
- 与传统的HCC相比,VETC-HCC的CD8透率显著降低.
结论:
- MTM-HCC和VETC-HCC具有不同的免疫表型和时间.
- 这两种亚型都有助于免疫抑制的时间,但通过不同的机制.
- 调节时间从抑制到活性是提高免疫检查点抑制剂在HCC中的有效性至关重要的.
相关概念视频
The Tumor Microenvironment
6.6K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.6K
Tumor Immunotherapy
524
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
524


